Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

41.86 +0.86 (+2.10%)
Streaming Delayed Price Updated: 12:40 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 Next >
News headline image
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at Upcoming Investor Conferences
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Reports Third Quarter 2025 Financial Results & Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Report Q3 2025 Financial Results on November 3, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Reports Second Quarter 2025 Financial Results & Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Report Q2 2025 Financial Results on August 11, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Joins the Russell 3000® and Russell 2000® Indexes
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Report Q1 2025 Financial Results on May 12, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at Stifel 2025 Virtual CNS Forum
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.